All In Biotech

Free tool

FAERS Monitor: Bystolic

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021742 or its brand name (Bystolic, Nebivolol Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

17,999

Serious

9,157

51% of reports

Hospitalization

4,412

Death reported

861

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue1,332
  • drug ineffective1,073
  • diarrhoea1,060
  • nausea1,030
  • headache982
  • dyspnoea936
  • dizziness906
  • off label use712
  • pain660
  • asthenia622
  • blood pressure increased587
  • arthralgia539
  • malaise518
  • hypertension517
  • fall511

Reports by year received

View as table
YearReports
20046
200510
20068
200712
200877
2009634
2010727
2011610
2012821
2013906
20141,056
20151,619
20161,982
20171,351
20181,643
20191,399
20201,160
2021840
2022917
2023681
2024628
2025539
2026373

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,160 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood pressure increasedSignal5874.54.21,600
hypertensionSignal5172.92.6627
dizzinessSignal9062.12.0550
fatigueSignal1,3322.01.9690
asthenia6221.91.8285
dyspnoea9361.91.8432
diarrhoea1,0601.91.8481
headache9821.81.7381
fall5111.81.6182
nausea1,0301.51.4190
arthralgia5391.51.496
malaise5181.41.355
pain6601.31.235
drug ineffective1,0731.00.93
off label use7121.00.92

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.